Does the media prefer ANIP or ADMA?

In the previous week, ADMA Biologics had 21 more articles in the media than ANI Pharmaceuticals. MarketBeat recorded 34 mentions for ADMA Biologics and 13 mentions for ANI Pharmaceuticals. ANI Pharmaceuticals' average media sentiment score of 0.63 beat ADMA Biologics' score of 0.11 indicating that ANI Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ANI Pharmaceuticals 7 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ADMA Biologics 1 Very Positive mention(s) 0 Positive mention(s) 32 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to ANIP or ANVS?

In the previous week, ANI Pharmaceuticals had 8 more articles in the media than Annovis Bio. MarketBeat recorded 13 mentions for ANI Pharmaceuticals and 5 mentions for Annovis Bio. Annovis Bio's average media sentiment score of 0.76 beat ANI Pharmaceuticals' score of 0.63 indicating that Annovis Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ANI Pharmaceuticals 7 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Annovis Bio 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor RYTM or ANIP?

In the previous week, ANI Pharmaceuticals had 9 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 13 mentions for ANI Pharmaceuticals and 4 mentions for Rhythm Pharmaceuticals. Rhythm Pharmaceuticals' average media sentiment score of 1.14 beat ANI Pharmaceuticals' score of 0.63 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rhythm Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ANI Pharmaceuticals 7 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer MIRM or ANIP?

In the previous week, ANI Pharmaceuticals had 1 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 13 mentions for ANI Pharmaceuticals and 12 mentions for Mirum Pharmaceuticals. Mirum Pharmaceuticals' average media sentiment score of 0.94 beat ANI Pharmaceuticals' score of 0.63 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mirum Pharmaceuticals 8 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ANI Pharmaceuticals 7 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ANIP or SYRE?

In the previous week, ANI Pharmaceuticals had 6 more articles in the media than Spyre Therapeutics. MarketBeat recorded 13 mentions for ANI Pharmaceuticals and 7 mentions for Spyre Therapeutics. Spyre Therapeutics' average media sentiment score of 0.97 beat ANI Pharmaceuticals' score of 0.63 indicating that Spyre Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ANI Pharmaceuticals 7 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Spyre Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

ANI Pharmaceuticals (ANIP) Competitors

$81.24 +0.69 (+0.86%)

As of 01:30 PM Eastern

Compare

ANIP vs. ADMA, ANVS, RYTM, MIRM, and SYRE

Should you buy ANI Pharmaceuticals stock or one of its competitors? MarketBeat compares ANI Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ANI Pharmaceuticals include ADMA Biologics (ADMA), Annovis Bio (ANVS), Rhythm Pharmaceuticals (RYTM), Mirum Pharmaceuticals (MIRM), and Spyre Therapeutics (SYRE). These companies are all part of the "pharmaceutical products" industry.

How does ANI Pharmaceuticals compare to ADMA Biologics?

ANI Pharmaceuticals (NASDAQ:ANIP) and ADMA Biologics (NASDAQ:ADMA) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, dividends, profitability, risk and analyst recommendations.

ADMA Biologics has lower revenue, but higher earnings than ANI Pharmaceuticals. ADMA Biologics is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ANI Pharmaceuticals	$883.37M	2.09	$78.34M	$3.95	20.57
ADMA Biologics	$509.86M	4.02	$146.93M	$0.68	12.99

ANI Pharmaceuticals has a beta of 0.43, indicating that its share price is 57% less volatile than the broader market. Comparatively, ADMA Biologics has a beta of 0.73, indicating that its share price is 27% less volatile than the broader market.

76.1% of ANI Pharmaceuticals shares are held by institutional investors. Comparatively, 75.7% of ADMA Biologics shares are held by institutional investors. 8.1% of ANI Pharmaceuticals shares are held by company insiders. Comparatively, 3.9% of ADMA Biologics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

ADMA Biologics has a net margin of 32.43% compared to ANI Pharmaceuticals' net margin of 9.98%. ADMA Biologics' return on equity of 39.98% beat ANI Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ANI Pharmaceuticals	9.98%	27.51%	10.02%
ADMA Biologics	32.43%	39.98%	28.08%

In the previous week, ADMA Biologics had 21 more articles in the media than ANI Pharmaceuticals. MarketBeat recorded 34 mentions for ADMA Biologics and 13 mentions for ANI Pharmaceuticals. ANI Pharmaceuticals' average media sentiment score of 0.63 beat ADMA Biologics' score of 0.11 indicating that ANI Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ANI Pharmaceuticals	7 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ADMA Biologics	1 Very Positive mention(s)	0 Positive mention(s)	32 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

ANI Pharmaceuticals currently has a consensus target price of $107.33, suggesting a potential upside of 32.12%. ADMA Biologics has a consensus target price of $18.67, suggesting a potential upside of 111.28%. Given ADMA Biologics' higher probable upside, analysts plainly believe ADMA Biologics is more favorable than ANI Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ANI Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75
ADMA Biologics	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

ANI Pharmaceuticals and ADMA Biologics tied by winning 8 of the 16 factors compared between the two stocks.

How does ANI Pharmaceuticals compare to Annovis Bio?

ANI Pharmaceuticals (NASDAQ:ANIP) and Annovis Bio (NYSE:ANVS) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, media sentiment, dividends, profitability, valuation and risk.

76.1% of ANI Pharmaceuticals shares are held by institutional investors. Comparatively, 15.8% of Annovis Bio shares are held by institutional investors. 8.1% of ANI Pharmaceuticals shares are held by insiders. Comparatively, 20.8% of Annovis Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

ANI Pharmaceuticals has higher revenue and earnings than Annovis Bio. Annovis Bio is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ANI Pharmaceuticals	$883.37M	2.09	$78.34M	$3.95	20.57
Annovis Bio	N/A	N/A	-$28.85M	-$1.71	N/A

ANI Pharmaceuticals has a net margin of 9.98% compared to Annovis Bio's net margin of 0.00%. ANI Pharmaceuticals' return on equity of 27.51% beat Annovis Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ANI Pharmaceuticals	9.98%	27.51%	10.02%
Annovis Bio	N/A	-318.08%	-215.47%

In the previous week, ANI Pharmaceuticals had 8 more articles in the media than Annovis Bio. MarketBeat recorded 13 mentions for ANI Pharmaceuticals and 5 mentions for Annovis Bio. Annovis Bio's average media sentiment score of 0.76 beat ANI Pharmaceuticals' score of 0.63 indicating that Annovis Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ANI Pharmaceuticals	7 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Annovis Bio	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ANI Pharmaceuticals currently has a consensus target price of $107.33, indicating a potential upside of 32.12%. Annovis Bio has a consensus target price of $11.67, indicating a potential upside of 561.00%. Given Annovis Bio's higher possible upside, analysts plainly believe Annovis Bio is more favorable than ANI Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ANI Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75
Annovis Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

ANI Pharmaceuticals has a beta of 0.43, suggesting that its stock price is 57% less volatile than the broader market. Comparatively, Annovis Bio has a beta of 1.19, suggesting that its stock price is 19% more volatile than the broader market.

Summary

ANI Pharmaceuticals beats Annovis Bio on 11 of the 16 factors compared between the two stocks.

How does ANI Pharmaceuticals compare to Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals (NASDAQ:RYTM) and ANI Pharmaceuticals (NASDAQ:ANIP) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, media sentiment, risk and earnings.

ANI Pharmaceuticals has a net margin of 9.98% compared to Rhythm Pharmaceuticals' net margin of -93.33%. ANI Pharmaceuticals' return on equity of 27.51% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rhythm Pharmaceuticals	-93.33%	-203.25%	-44.99%
ANI Pharmaceuticals	9.98%	27.51%	10.02%

76.1% of ANI Pharmaceuticals shares are held by institutional investors. 5.9% of Rhythm Pharmaceuticals shares are held by company insiders. Comparatively, 8.1% of ANI Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, ANI Pharmaceuticals had 9 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 13 mentions for ANI Pharmaceuticals and 4 mentions for Rhythm Pharmaceuticals. Rhythm Pharmaceuticals' average media sentiment score of 1.14 beat ANI Pharmaceuticals' score of 0.63 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rhythm Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ANI Pharmaceuticals	7 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ANI Pharmaceuticals has higher revenue and earnings than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rhythm Pharmaceuticals	$189.76M	39.53	-$196.54M	-$3.13	N/A
ANI Pharmaceuticals	$883.37M	2.09	$78.34M	$3.95	20.57

Rhythm Pharmaceuticals currently has a consensus target price of $138.29, suggesting a potential upside of 26.33%. ANI Pharmaceuticals has a consensus target price of $107.33, suggesting a potential upside of 32.12%. Given ANI Pharmaceuticals' higher possible upside, analysts clearly believe ANI Pharmaceuticals is more favorable than Rhythm Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rhythm Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.76
ANI Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75

Rhythm Pharmaceuticals has a beta of 1.88, suggesting that its stock price is 88% more volatile than the broader market. Comparatively, ANI Pharmaceuticals has a beta of 0.43, suggesting that its stock price is 57% less volatile than the broader market.

Summary

ANI Pharmaceuticals beats Rhythm Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does ANI Pharmaceuticals compare to Mirum Pharmaceuticals?

Mirum Pharmaceuticals (NASDAQ:MIRM) and ANI Pharmaceuticals (NASDAQ:ANIP) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, media sentiment, institutional ownership, earnings, dividends and profitability.

Mirum Pharmaceuticals currently has a consensus price target of $143.40, indicating a potential upside of 19.22%. ANI Pharmaceuticals has a consensus price target of $107.33, indicating a potential upside of 32.12%. Given ANI Pharmaceuticals' higher possible upside, analysts plainly believe ANI Pharmaceuticals is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
ANI Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75

ANI Pharmaceuticals has higher revenue and earnings than Mirum Pharmaceuticals. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mirum Pharmaceuticals	$521.31M	14.07	-$23.36M	-$13.61	N/A
ANI Pharmaceuticals	$883.37M	2.09	$78.34M	$3.95	20.57

76.1% of ANI Pharmaceuticals shares are held by institutional investors. 8.3% of Mirum Pharmaceuticals shares are held by company insiders. Comparatively, 8.1% of ANI Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

ANI Pharmaceuticals has a net margin of 9.98% compared to Mirum Pharmaceuticals' net margin of -140.24%. ANI Pharmaceuticals' return on equity of 27.51% beat Mirum Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%
ANI Pharmaceuticals	9.98%	27.51%	10.02%

In the previous week, ANI Pharmaceuticals had 1 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 13 mentions for ANI Pharmaceuticals and 12 mentions for Mirum Pharmaceuticals. Mirum Pharmaceuticals' average media sentiment score of 0.94 beat ANI Pharmaceuticals' score of 0.63 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mirum Pharmaceuticals	8 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ANI Pharmaceuticals	7 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Mirum Pharmaceuticals has a beta of 0.48, indicating that its stock price is 52% less volatile than the broader market. Comparatively, ANI Pharmaceuticals has a beta of 0.43, indicating that its stock price is 57% less volatile than the broader market.

Summary

ANI Pharmaceuticals beats Mirum Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does ANI Pharmaceuticals compare to Spyre Therapeutics?

ANI Pharmaceuticals (NASDAQ:ANIP) and Spyre Therapeutics (NASDAQ:SYRE) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, dividends, risk, profitability, institutional ownership, earnings, analyst recommendations and valuation.

76.1% of ANI Pharmaceuticals shares are owned by institutional investors. Comparatively, 80.4% of Spyre Therapeutics shares are owned by institutional investors. 8.1% of ANI Pharmaceuticals shares are owned by insiders. Comparatively, 15.7% of Spyre Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

ANI Pharmaceuticals has higher revenue and earnings than Spyre Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ANI Pharmaceuticals	$883.37M	2.09	$78.34M	$3.95	20.57
Spyre Therapeutics	$890K	9,993.05	-$155.20M	-$2.08	N/A

ANI Pharmaceuticals has a beta of 0.43, suggesting that its share price is 57% less volatile than the broader market. Comparatively, Spyre Therapeutics has a beta of 3.02, suggesting that its share price is 202% more volatile than the broader market.

ANI Pharmaceuticals has a net margin of 9.98% compared to Spyre Therapeutics' net margin of 0.00%. ANI Pharmaceuticals' return on equity of 27.51% beat Spyre Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ANI Pharmaceuticals	9.98%	27.51%	10.02%
Spyre Therapeutics	N/A	-42.88%	-27.76%

In the previous week, ANI Pharmaceuticals had 6 more articles in the media than Spyre Therapeutics. MarketBeat recorded 13 mentions for ANI Pharmaceuticals and 7 mentions for Spyre Therapeutics. Spyre Therapeutics' average media sentiment score of 0.97 beat ANI Pharmaceuticals' score of 0.63 indicating that Spyre Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ANI Pharmaceuticals	7 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Spyre Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ANI Pharmaceuticals currently has a consensus target price of $107.33, indicating a potential upside of 32.12%. Spyre Therapeutics has a consensus target price of $101.42, indicating a potential upside of 0.28%. Given ANI Pharmaceuticals' higher possible upside, analysts plainly believe ANI Pharmaceuticals is more favorable than Spyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ANI Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75
Spyre Therapeutics	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.92

Summary

ANI Pharmaceuticals beats Spyre Therapeutics on 9 of the 17 factors compared between the two stocks.

Get ANI Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ANIP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ANIP vs. The Competition

Export

Metric	ANI Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.85B	$3.66B	$6.78B	$12.59B
Dividend Yield	N/A	2.19%	2.68%	8.43%
P/E Ratio	20.59	21.63	27.11	24.33
Price / Sales	2.09	326.37	525.10	92.04
Price / Cash	8.16	143.66	48.59	59.39
Price / Book	3.38	8.50	10.82	6.30
Net Income	$78.34M	$23.88M	$3.59B	$331.45M
7 Day Performance	-4.16%	-3.22%	-1.53%	-0.08%
1 Month Performance	-1.28%	5.42%	2.75%	-0.96%
1 Year Performance	26.94%	51.50%	28.40%	19.89%

ANI Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ANIP ANI Pharmaceuticals	4.0827 of 5 stars	$81.24 +0.9%	$107.33 +32.1%	+23.6%	$1.85B	$883.37M	20.59	600
ADMA ADMA Biologics	4.4615 of 5 stars	$9.16 +2.3%	$19.67 +114.7%	-52.5%	$2.07B	$510.17M	13.47	530	Trending News Analyst Forecast
ANVS Annovis Bio	3.4212 of 5 stars	$1.98 +2.3%	$13.50 +583.5%	-40.5%	$66.87M	N/A	N/A	3
RYTM Rhythm Pharmaceuticals	3.0514 of 5 stars	$111.68 -2.2%	$136.13 +21.9%	+23.3%	$7.82B	$189.76M	N/A	140	Positive News
MIRM Mirum Pharmaceuticals	2.7156 of 5 stars	$121.91 -2.9%	$143.00 +17.3%	+126.9%	$7.66B	$521.31M	N/A	140

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ANIP) was last updated on 7/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ANI Pharmaceuticals (ANIP) Competitors

ANIP vs. ADMA, ANVS, RYTM, MIRM, and SYRE

How does ANI Pharmaceuticals compare to ADMA Biologics?

Summary

How does ANI Pharmaceuticals compare to Annovis Bio?

Summary

How does ANI Pharmaceuticals compare to Rhythm Pharmaceuticals?

Summary

How does ANI Pharmaceuticals compare to Mirum Pharmaceuticals?

Summary

How does ANI Pharmaceuticals compare to Spyre Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANIP vs. The Competition

ANI Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ANI Pharmaceuticals (ANIP) Competitors

ANIP vs. ADMA, ANVS, RYTM, MIRM, and SYRE

How does ANI Pharmaceuticals compare to ADMA Biologics?

Which has better valuation and earnings, ANIP or ADMA?

Which has more volatility and risk, ANIP or ADMA?

Do institutionals and insiders have more ownership in ANIP or ADMA?

Is ANIP or ADMA more profitable?

Does the media prefer ANIP or ADMA?

Do analysts rate ANIP or ADMA?

Summary

How does ANI Pharmaceuticals compare to Annovis Bio?

Do insiders & institutionals believe in ANIP or ANVS?

Which has stronger earnings & valuation, ANIP or ANVS?

Is ANIP or ANVS more profitable?

Does the media refer more to ANIP or ANVS?

Do analysts recommend ANIP or ANVS?

Which has more risk & volatility, ANIP or ANVS?

Summary

How does ANI Pharmaceuticals compare to Rhythm Pharmaceuticals?

Is RYTM or ANIP more profitable?

Do insiders & institutionals have more ownership in RYTM or ANIP?

Does the media favor RYTM or ANIP?

Which has higher earnings & valuation, RYTM or ANIP?

Do analysts rate RYTM or ANIP?

Which has more risk & volatility, RYTM or ANIP?

Summary

How does ANI Pharmaceuticals compare to Mirum Pharmaceuticals?

Do analysts recommend MIRM or ANIP?

Which has higher valuation & earnings, MIRM or ANIP?

Do insiders and institutionals believe in MIRM or ANIP?

Is MIRM or ANIP more profitable?

Does the media prefer MIRM or ANIP?

Which has more risk and volatility, MIRM or ANIP?

Summary

How does ANI Pharmaceuticals compare to Spyre Therapeutics?

Do insiders & institutionals believe in ANIP or SYRE?

Which has better valuation & earnings, ANIP or SYRE?

Which has more risk & volatility, ANIP or SYRE?

Is ANIP or SYRE more profitable?

Does the media favor ANIP or SYRE?

Do analysts recommend ANIP or SYRE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANIP vs. The Competition

ANI Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools